Isolation of neuroprotective alkaloids from Ormosia henryi shows significant AChE inhibition and cell protection effects.
Two pairs of undescribed alkaloid enantiomers, (+)-/(−)-ormohenins A ( 1 ) and B ( 2 ), were isolated from the seeds of Ormosia henryi Prain, along with four undescribed alkaloids ( 3 , 4 , 7 and 8 ) and seven known ones ( 5 , 6 , 9 – 13 ). Compounds 1 – 6 belong to the ormosanine-type alkaloids, compounds 7 , 9 , and 11 are of the lupinine-type, compounds 8 and 10 are classified as anagyrine-type alkaloids, 12 and 13 are cytisine-type alkaloids. The chemical structures of 1 – 13 were elucidated through comprehensive NMR and MS data analyses. Furthermore, the racemates (±)- 1 and (±)- 2 were successfully resolved into their respective optically pure enantiomers using a chiral HPLC system. The absolute configurations of compounds 1–3 were determined using single-crystal X-ray diffraction and corroborated by DFT calculations of specific rotations. The absolute configurations of 4 , 7 , and 8 were assigned by the experimental electronic circular dichroism (ECD) with those predicted using TDDFT calculations. Compound 12 exhibited significant acetylcholinesterase (AChE) inhibitory activity with the IC 50 value of 6.581 ± 1.203 μM. The neuroprotective effects of these compounds against A β 25-35 induced cell damage in PC12 cells were investigated, and compounds 3 , 9 , and 12 exhibited significant neuroprotective effects against A β 25-35 induced PC12 cell damage, with the EC 50 values of 7.99–15.49 μM, respectively.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: